Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892296087> ?p ?o ?g. }
- W2892296087 endingPage "73" @default.
- W2892296087 startingPage "66" @default.
- W2892296087 abstract "Lennox-Gastaut syndrome (LGS) is a severe and treatment-resistant epilepsy syndrome characterized by multiple subtypes of intractable seizures, moderate to severe cognitive impairment, and slow spike-wave complexes on electroencephalographic (EEG) recordings. Lennox-Gastaut syndrome is also associated with increased risk for injury, reduced quality of life, long-term disability, and early mortality. By evaluating private and public US medical insurance claims, we quantified healthcare utilization and direct costs in patients with possible LGS.Commercial and Medicaid insurance claims (Truven Health Analytics) from October 2010 to September 2015 were queried to identify patients with intractable epilepsy, intellectual disability, ≥1 prescription for selected antiepileptic drugs (AEDs), and ≥2 years of continuous enrollment. To identify patients with LGS in the absence of a specific International Classification of Diseases ICD-9 diagnosis code, current or prior rufinamide use was selected as a disease indicator of LGS per previously published methodology. Characteristics significantly predictive of rufinamide use were identified with multivariate regression by comparing groups with and without LGS, then assessed in non-rufinamide users fulfilling all other inclusion criteria. Controls without epilepsy, seizures, or prescriptions for selected AEDs were matched to patients with possible LGS by age, gender, US region, and dates of insurance coverage. Average healthcare utilization and costs per patient per year (PPPY) were evaluated for a 2-year postindex period and compared between the cohort with LGS and controls by insurance type. Costs were normalized to 2017 dollars at 3% per annum.In the study, 6019 patients with possible LGS (53% male, mean age of 13 years, in both insurance groups) were identified: 2270 with commercial insurance and 3749 with Medicaid. The cohort with LGS used >8 times more services and >7 times more drugs than controls (all p < 0.001) in both insurance groups. The biggest contributors to service use PPPY were outpatient physician visits and home health services in the commercial-insured cohort with LGS and other outpatient visits and home health services in the Medicaid-insured cohort with LGS. Average total costs PPPY (services + drugs) were significantly higher for the cohort with LGS vs. controls: $65,026 (SD $34,324) vs. $2442 (SD $10,670) for commercial-insured and $63,930 (SD $45,761) vs. $3849 (SD $13849) for Medicaid-insured patients. The biggest cost contributors PPPY were inpatient care in the commercial-insured cohort with LGS and home health services in the Medicaid-insured cohort with LGS.Patients with possible LGS have significantly higher healthcare utilization and costs than patients without epilepsy or seizures. Our results suggest that direct costs associated with LGS are substantial and highlight the need for new and effective treatments." @default.
- W2892296087 created "2018-09-27" @default.
- W2892296087 creator A5008175024 @default.
- W2892296087 creator A5017344875 @default.
- W2892296087 creator A5023000375 @default.
- W2892296087 creator A5027426540 @default.
- W2892296087 creator A5085037662 @default.
- W2892296087 date "2018-11-01" @default.
- W2892296087 modified "2023-09-25" @default.
- W2892296087 title "Burden of illness in patients with possible Lennox–Gastaut syndrome: A retrospective claims-based study" @default.
- W2892296087 cites W1502791410 @default.
- W2892296087 cites W1671458509 @default.
- W2892296087 cites W1984182316 @default.
- W2892296087 cites W1995799480 @default.
- W2892296087 cites W2000739510 @default.
- W2892296087 cites W2039792054 @default.
- W2892296087 cites W2071377083 @default.
- W2892296087 cites W2078196673 @default.
- W2892296087 cites W2100428079 @default.
- W2892296087 cites W2110876059 @default.
- W2892296087 cites W2137728866 @default.
- W2892296087 cites W2156196899 @default.
- W2892296087 cites W2607056020 @default.
- W2892296087 cites W2622310395 @default.
- W2892296087 cites W2785059893 @default.
- W2892296087 cites W2804921146 @default.
- W2892296087 doi "https://doi.org/10.1016/j.yebeh.2018.08.032" @default.
- W2892296087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30241056" @default.
- W2892296087 hasPublicationYear "2018" @default.
- W2892296087 type Work @default.
- W2892296087 sameAs 2892296087 @default.
- W2892296087 citedByCount "12" @default.
- W2892296087 countsByYear W28922960872019 @default.
- W2892296087 countsByYear W28922960872020 @default.
- W2892296087 countsByYear W28922960872021 @default.
- W2892296087 countsByYear W28922960872022 @default.
- W2892296087 countsByYear W28922960872023 @default.
- W2892296087 crossrefType "journal-article" @default.
- W2892296087 hasAuthorship W2892296087A5008175024 @default.
- W2892296087 hasAuthorship W2892296087A5017344875 @default.
- W2892296087 hasAuthorship W2892296087A5023000375 @default.
- W2892296087 hasAuthorship W2892296087A5027426540 @default.
- W2892296087 hasAuthorship W2892296087A5085037662 @default.
- W2892296087 hasBestOaLocation W28922960871 @default.
- W2892296087 hasConcept C118552586 @default.
- W2892296087 hasConcept C126322002 @default.
- W2892296087 hasConcept C159110408 @default.
- W2892296087 hasConcept C160735492 @default.
- W2892296087 hasConcept C162324750 @default.
- W2892296087 hasConcept C167135981 @default.
- W2892296087 hasConcept C187212893 @default.
- W2892296087 hasConcept C2426938 @default.
- W2892296087 hasConcept C2776534028 @default.
- W2892296087 hasConcept C2778186239 @default.
- W2892296087 hasConcept C2779307984 @default.
- W2892296087 hasConcept C2779951463 @default.
- W2892296087 hasConcept C2908647359 @default.
- W2892296087 hasConcept C45827449 @default.
- W2892296087 hasConcept C50522688 @default.
- W2892296087 hasConcept C551499885 @default.
- W2892296087 hasConcept C71924100 @default.
- W2892296087 hasConcept C72563966 @default.
- W2892296087 hasConcept C98274493 @default.
- W2892296087 hasConcept C99454951 @default.
- W2892296087 hasConceptScore W2892296087C118552586 @default.
- W2892296087 hasConceptScore W2892296087C126322002 @default.
- W2892296087 hasConceptScore W2892296087C159110408 @default.
- W2892296087 hasConceptScore W2892296087C160735492 @default.
- W2892296087 hasConceptScore W2892296087C162324750 @default.
- W2892296087 hasConceptScore W2892296087C167135981 @default.
- W2892296087 hasConceptScore W2892296087C187212893 @default.
- W2892296087 hasConceptScore W2892296087C2426938 @default.
- W2892296087 hasConceptScore W2892296087C2776534028 @default.
- W2892296087 hasConceptScore W2892296087C2778186239 @default.
- W2892296087 hasConceptScore W2892296087C2779307984 @default.
- W2892296087 hasConceptScore W2892296087C2779951463 @default.
- W2892296087 hasConceptScore W2892296087C2908647359 @default.
- W2892296087 hasConceptScore W2892296087C45827449 @default.
- W2892296087 hasConceptScore W2892296087C50522688 @default.
- W2892296087 hasConceptScore W2892296087C551499885 @default.
- W2892296087 hasConceptScore W2892296087C71924100 @default.
- W2892296087 hasConceptScore W2892296087C72563966 @default.
- W2892296087 hasConceptScore W2892296087C98274493 @default.
- W2892296087 hasConceptScore W2892296087C99454951 @default.
- W2892296087 hasLocation W28922960871 @default.
- W2892296087 hasLocation W28922960872 @default.
- W2892296087 hasOpenAccess W2892296087 @default.
- W2892296087 hasPrimaryLocation W28922960871 @default.
- W2892296087 hasRelatedWork W2035277224 @default.
- W2892296087 hasRelatedWork W2040021578 @default.
- W2892296087 hasRelatedWork W2089104512 @default.
- W2892296087 hasRelatedWork W2481474031 @default.
- W2892296087 hasRelatedWork W2524115679 @default.
- W2892296087 hasRelatedWork W2763503006 @default.
- W2892296087 hasRelatedWork W2890039708 @default.
- W2892296087 hasRelatedWork W2893276243 @default.
- W2892296087 hasRelatedWork W2905654921 @default.
- W2892296087 hasRelatedWork W3112524606 @default.